Updated · The Atlanta Journal Constitution · Jun 11
Georgia Hospitals Test FDA-Approved Daraxonrasib for Metastatic Pancreatic Cancer, Doubling Survival to 13 Months
Updated
Updated · The Atlanta Journal Constitution · Jun 11
Georgia Hospitals Test FDA-Approved Daraxonrasib for Metastatic Pancreatic Cancer, Doubling Survival to 13 Months
3 articles · Updated · The Atlanta Journal Constitution · Jun 11
Summary
Daraxonrasib is now being tested at Georgia centers including Emory Winship and Piedmont after the FDA granted early access in May for metastatic pancreatic cancer.
13 months of median survival and about 7 months of progression-free survival were reported in trial patients, roughly double outcomes typically seen with standard chemotherapy.
KRAS mutations appear in more than 90% of pancreatic cancers, and the daily oral drug targets that pathway while causing fewer side effects than intravenous chemotherapy, mainly mild skin rashes.
David Stockton, 70, and Sarah Menning, 77, described major gains in daily function after entering clinical trials, underscoring hopes for a disease that is usually found late and remains one of the deadliest cancers.
Eli Lilly and Revolution Medicines are expanding studies of KRAS inhibitors nationwide, and oncologists say the approach could broaden treatment options for pancreatic cancer beyond chemotherapy.